Pharma company Cipla disclosed a 54.6% decrease in its consolidated net profit for the fourth quarter of FY26, citing an impairment charge as the main reason. The company’s revenue also experienced a slight drop year-on-year. In specific numbers, Cipla’s consolidated net profit for the January-March quarter was Rs 554.64 crore, down from Rs 1,221.84 crore in the same period of the previous financial year.
Revenue from operations during Q4 FY26 was reported at Rs 6,541.20 crore, showing a 2.80% decline compared to the year-ago period. The company’s EBITDA for the quarter fell by 38% to Rs 955 crore from Rs 1,537.6 crore in the corresponding period of the previous financial year. Additionally, the EBITDA margin contracted significantly to 14.6% from 22.80% on a year-on-year basis.
During the quarter and financial year ending March 31, 2026, Cipla recorded an impairment charge of Rs 42.02 crore related to associates due to changes in business conditions and market dynamics. Excluding this impairment impact, the company’s EBITDA for the quarter would have been Rs 997 crore, with an EBITDA margin of 15.2%.
The Board of Directors of Cipla proposed a final dividend of Rs 13 per equity share for the financial year ending March 31, 2026. The dividend, subject to shareholder approval at the Annual General Meeting, is scheduled to be paid within 30 days from the AGM date. June 5, 2026, was announced as the record date for determining eligible shareholders for the final dividend payout.
In response to the earnings announcement, Cipla’s shares saw an increase in trading value. At 1:34 PM, Cipla stock was up by 3.7% at Rs 1,340.70 apiece on the NSE.
